



Dynogen Pharmaceuticals, Inc.

52 Second Avenue
Waltham, MA 02451

TEL: 781-839-5100
FAX: 781-839-5200

www.dynogen.com

P R E S S R E L E A S E

For information contact:

Heather Savelle
Dynogen Pharmaceuticals, Inc.
(781) 839-5149
hsavelle@dynogen.com

Media:

Douglas MacDougall
MacDougall Biomedical Communications
(781) 235-3060
dmacdougall@macbiocom.com

**DYNNOGEN ANNOUNCES POSITIVE RESULTS IN PHASE 2 IBS-D STUDY
- DDP225 Results Mark Dynogen's Third Set of Positive Proof of Concept Data This Year -**

WALTHAM, Mass., December 17, 2007 – Dynogen Pharmaceuticals, Inc. today announced positive results from its Phase 2 trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d). The randomized, double-blind, placebo controlled trial generated statistically significant results for the clinical endpoint of relief from abdominal pain or discomfort associated with IBS-d. Detailed results will be submitted for disclosure in a peer-reviewed journal or at a future medical conference.

The 1 mg dose of DDP225 administered once daily for eight weeks achieved a 71% response rate compared to a 25% response rate for placebo in the prospectively defined clinical endpoint of adequate relief of IBS pain or discomfort. This was a statistically significant ($p=0.009$) benefit over placebo using an efficacy measure accepted by the FDA as the basis for approval for treatment of IBS-d. Dynogen's Phase 2 trial enrolled 87 women at multiple centers in the U.S. and Canada. DDP225 was safe and well tolerated in this study.

“The high response rate together with the 46% separation from placebo seen in this Phase 2 study demonstrates compelling proof of concept for DDP225 as a treatment for IBS-d,” commented Dr. Suhail Nurbhai, MRCP, Vice President of Clinical Development at Dynogen. “IBS-d is a painful and debilitating condition for which current therapy is extremely limited, and we look forward to initiating a Phase 2b trial of DDP225 in 2008.”

“The DDP225 results mark the third set of positive proof of concept data to come from Dynogen's clinical development pipeline within the last year and position us as the only company with advanced stage programs in both IBS-c and IBS-d,” said Dr. Lee R. Brettman, M.D., Dynogen's President and Chief Executive Officer. “We are on track to have four Phase 3-ready programs within the next 24 months, based on these data and positive results in our planned trials.”

About DDP225

DDP225 is an oral noradrenaline reuptake inhibitor (NARI) and a weak 5HT₃ receptor antagonist that Dynogen is developing for IBS-d. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and weak 5HT₃ antagonism in one orally delivered compound represents a novel approach to treating IBS-d, enabling efficacy to be achieved at very low and well tolerated doses of DDP225. Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Tanabe Pharma in October 2003. It has been dosed to over 450 human subjects for durations up to 12 weeks, and at single doses up to 100 mg. Dynogen owns issued patents and pending patent applications related to the use of DDP225 as a treatment for IBS.

About Irritable Bowel Syndrome (IBS)

IBS affects approximately 12% of the U.S. population, or 27 million patients. IBS is a chronic disease characterized by abdominal pain and discomfort associated with altered bowel habit. IBS is associated with \$1.6 billion in direct medical costs and \$19.2 in indirect costs in the U.S. each year. Patients with IBS make an average of 5.5 visits to the physician each year compared to 1.9 visits annually for people without bowel symptoms. Additionally, people with IBS incur healthcare costs nearly 50% higher than the average American, and miss three times as many day of work. Zelnorm[®] (tegaserod, Novartis) was the only approved drug for IBS with constipation (IBS-c) and was suspended from marketing by the FDA in March 2007, except in rare and restrictive cases. Lotronex[®] (alosetron, GSK) is the only drug approved by the FDA for the treatment of IBS-d, but its use is restricted to women with severe disease who have not responded adequately to other therapies and is subject to a comprehensive and restrictive prescribing program.

About Dynogen Pharmaceuticals, Inc.

Dynogen is a clinical-stage company developing a portfolio of treatments for gastrointestinal and genitourinary disorders. The Company is focused on large and underserved markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The Company leverages its development expertise to identify promising clinical compounds and rapidly advance them towards registration. www.dynogen.com

#